GSK (GSK) said Wednesday it has completed the acquisition of Nuvalent (NUVL), a Boston-based clinical-stage biopharmaceutical company, in a transaction with an aggregate equity value of about $10.6 billion.
The transaction, which represents a net investment of about $9.4 billion after accounting for acquired cash, was finalized through a tender offer for all outstanding Nuvalent shares.
The deal adds three lung cancer assets to GSK's oncology portfolio, according to a statement.
Price: 51.55, Change: +0.30, Percent Change: +0.58
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments